Evaluating Efficacy of Antimicrobial and Antifouling Materials for Urinary Tract Medical Devices: Challenges and Recommendations

Madeleine Ramstedt; Isabel A.C. Ribeiro; Helena Bujdakova; Filipe J.M. Mergulhão; Luisa Jordao; Peter Thomsen; Martin Alm; Mette Burmølle; Todorka Vladkova; Fusun Can; Meital Reches; Martijn Riool; Alexandre Barros; Rui L. Reis; Emilio Meaurio; Judith Kikhney; Annette Moter; Sebastian A.J. Zaat; Jelmer Sjollema

doi:10.1002/mabi.201800384

Evaluating Efficacy of Antimicrobial and Antifouling Materials for Urinary Tract Medical Devices: Challenges and Recommendations

Madeleine Ramstedt^*, Isabel A.C. Ribeiro, Helena Bujdakova, Filipe J.M. Mergulhão, Luisa Jordao, Peter Thomsen, Martin Alm, Mette Burmølle, Todorka Vladkova, Fusun Can, Meital Reches, Martijn Riool, Alexandre Barros, Rui L. Reis, Emilio Meaurio, Judith Kikhney, Annette Moter, Sebastian A.J. Zaat, Jelmer Sjollema

^*Corresponding author for this work

Institute of Chemistry

Research output: Contribution to journal › Review article › peer-review

65 Scopus citations

Abstract

In Europe, the mean incidence of urinary tract infections in intensive care units is 1.1 per 1000 patient-days. Of these cases, catheter-associated urinary tract infections (CAUTI) account for 98%. In total, CAUTI in hospitals is estimated to give additional health-care costs of £1–2.5 billion in the United Kingdom alone. This is in sharp contrast to the low cost of urinary catheters and emphasizes the need for innovative products that reduce the incidence rate of CAUTI. Ureteral stents and other urinary-tract devices suffer similar problems. Antimicrobial strategies are being developed, however, the evaluation of their efficacy is very challenging. This review aims to provide considerations and recommendations covering all relevant aspects of antimicrobial material testing, including surface characterization, biocompatibility, cytotoxicity, in vitro and in vivo tests, microbial strain selection, and hydrodynamic conditions, all in the perspective of complying to the complex pathology of device-associated urinary tract infection. The recommendations should be on the basis of standard assays to be developed which would enable comparisons of results obtained in different research labs both in industry and in academia, as well as provide industry and academia with tools to assess the antimicrobial properties for urinary tract devices in a reliable way.

Original language	American English
Article number	1800384
Journal	Macromolecular Bioscience
Volume	19
Issue number	5
DOIs	https://doi.org/10.1002/mabi.201800384
State	Published - May 2019

Bibliographical note

Funding Information:
This perspective review has been written as a part of the EU-funded Trans Domain COST Action, TD 1305 iPROMEDAI (improved protection of medical devices against infection), in the focus group for urinary tract devices. The aim of the work performed in this group has been to bridge different areas of expertise, discuss and give suggestions for ways in which testing of medical devices aimed at preventing infection should be performed to follow best practices, as well as to enhance the predictability of methods for clinical outcome of a device with respect to infection. The authors would like to acknowledge COST (European Cooperation in Science and Technology) for funding of the network, as well as network participants that have given input in discussions forming the base for this paper, including Dr. Cesar Rodrigues-Emmenegger, Prof. Erik Reimhult, Prof. Peter Tenke, Dr. Botond Lakatos, Dr. Naseem Theilgaard, Dr. Reto Luginbuehl, Prof. Yannis Missirlis, Dr. Matthias Buhmann, Dr. Vesna Miskovic-Stankovic, Dr. Veronique Fontaine, Dr. Jose-Ramon Sarasua. Project PTDC/BTM-SAL/29335/2017, Portuguese Government, Fundação para a Ciência e Tecnologia (FCT), and designer Nuno Monge is acknowledged for assistance with the artworks of Figures, and.

Publisher Copyright:
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

Keywords

antimicrobial
device-associated urinary tract infections
in vitro
in vivo
material testing

Access to Document

10.1002/mabi.201800384

Cite this

Ramstedt, M., Ribeiro, I. A. C., Bujdakova, H., Mergulhão, F. J. M., Jordao, L., Thomsen, P., Alm, M., Burmølle, M., Vladkova, T., Can, F., Reches, M., Riool, M., Barros, A., Reis, R. L., Meaurio, E., Kikhney, J., Moter, A., Zaat, S. A. J., & Sjollema, J. (2019). Evaluating Efficacy of Antimicrobial and Antifouling Materials for Urinary Tract Medical Devices: Challenges and Recommendations. Macromolecular Bioscience, 19(5), Article 1800384. https://doi.org/10.1002/mabi.201800384

@article{c428a27505774e2ba00890bb35922f3a,

title = "Evaluating Efficacy of Antimicrobial and Antifouling Materials for Urinary Tract Medical Devices: Challenges and Recommendations",

abstract = "In Europe, the mean incidence of urinary tract infections in intensive care units is 1.1 per 1000 patient-days. Of these cases, catheter-associated urinary tract infections (CAUTI) account for 98%. In total, CAUTI in hospitals is estimated to give additional health-care costs of £1–2.5 billion in the United Kingdom alone. This is in sharp contrast to the low cost of urinary catheters and emphasizes the need for innovative products that reduce the incidence rate of CAUTI. Ureteral stents and other urinary-tract devices suffer similar problems. Antimicrobial strategies are being developed, however, the evaluation of their efficacy is very challenging. This review aims to provide considerations and recommendations covering all relevant aspects of antimicrobial material testing, including surface characterization, biocompatibility, cytotoxicity, in vitro and in vivo tests, microbial strain selection, and hydrodynamic conditions, all in the perspective of complying to the complex pathology of device-associated urinary tract infection. The recommendations should be on the basis of standard assays to be developed which would enable comparisons of results obtained in different research labs both in industry and in academia, as well as provide industry and academia with tools to assess the antimicrobial properties for urinary tract devices in a reliable way.",

keywords = "antimicrobial, device-associated urinary tract infections, in vitro, in vivo, material testing",

author = "Madeleine Ramstedt and Ribeiro, {Isabel A.C.} and Helena Bujdakova and Mergulh{\~a}o, {Filipe J.M.} and Luisa Jordao and Peter Thomsen and Martin Alm and Mette Burm{\o}lle and Todorka Vladkova and Fusun Can and Meital Reches and Martijn Riool and Alexandre Barros and Reis, {Rui L.} and Emilio Meaurio and Judith Kikhney and Annette Moter and Zaat, {Sebastian A.J.} and Jelmer Sjollema",

note = "Funding Information: This perspective review has been written as a part of the EU-funded Trans Domain COST Action, TD 1305 iPROMEDAI (improved protection of medical devices against infection), in the focus group for urinary tract devices. The aim of the work performed in this group has been to bridge different areas of expertise, discuss and give suggestions for ways in which testing of medical devices aimed at preventing infection should be performed to follow best practices, as well as to enhance the predictability of methods for clinical outcome of a device with respect to infection. The authors would like to acknowledge COST (European Cooperation in Science and Technology) for funding of the network, as well as network participants that have given input in discussions forming the base for this paper, including Dr. Cesar Rodrigues-Emmenegger, Prof. Erik Reimhult, Prof. Peter Tenke, Dr. Botond Lakatos, Dr. Naseem Theilgaard, Dr. Reto Luginbuehl, Prof. Yannis Missirlis, Dr. Matthias Buhmann, Dr. Vesna Miskovic-Stankovic, Dr. Veronique Fontaine, Dr. Jose-Ramon Sarasua. Project PTDC/BTM-SAL/29335/2017, Portuguese Government, Funda{\c c}{\~a}o para a Ci{\^e}ncia e Tecnologia (FCT), and designer Nuno Monge is acknowledged for assistance with the artworks of Figures, and. Publisher Copyright: {\textcopyright} 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim",

year = "2019",

month = may,

doi = "10.1002/mabi.201800384",

language = "American English",

volume = "19",

journal = "Macromolecular Bioscience",

issn = "1616-5187",

publisher = "Wiley-VCH Verlag",

number = "5",

}

Ramstedt, M, Ribeiro, IAC, Bujdakova, H, Mergulhão, FJM, Jordao, L, Thomsen, P, Alm, M, Burmølle, M, Vladkova, T, Can, F, Reches, M, Riool, M, Barros, A, Reis, RL, Meaurio, E, Kikhney, J, Moter, A, Zaat, SAJ & Sjollema, J 2019, 'Evaluating Efficacy of Antimicrobial and Antifouling Materials for Urinary Tract Medical Devices: Challenges and Recommendations', Macromolecular Bioscience, vol. 19, no. 5, 1800384. https://doi.org/10.1002/mabi.201800384

TY - JOUR

T1 - Evaluating Efficacy of Antimicrobial and Antifouling Materials for Urinary Tract Medical Devices

T2 - Challenges and Recommendations

AU - Ramstedt, Madeleine

AU - Ribeiro, Isabel A.C.

AU - Bujdakova, Helena

AU - Mergulhão, Filipe J.M.

AU - Jordao, Luisa

AU - Thomsen, Peter

AU - Alm, Martin

AU - Burmølle, Mette

AU - Vladkova, Todorka

AU - Can, Fusun

AU - Reches, Meital

AU - Riool, Martijn

AU - Barros, Alexandre

AU - Reis, Rui L.

AU - Meaurio, Emilio

AU - Kikhney, Judith

AU - Moter, Annette

AU - Zaat, Sebastian A.J.

AU - Sjollema, Jelmer

N1 - Funding Information: This perspective review has been written as a part of the EU-funded Trans Domain COST Action, TD 1305 iPROMEDAI (improved protection of medical devices against infection), in the focus group for urinary tract devices. The aim of the work performed in this group has been to bridge different areas of expertise, discuss and give suggestions for ways in which testing of medical devices aimed at preventing infection should be performed to follow best practices, as well as to enhance the predictability of methods for clinical outcome of a device with respect to infection. The authors would like to acknowledge COST (European Cooperation in Science and Technology) for funding of the network, as well as network participants that have given input in discussions forming the base for this paper, including Dr. Cesar Rodrigues-Emmenegger, Prof. Erik Reimhult, Prof. Peter Tenke, Dr. Botond Lakatos, Dr. Naseem Theilgaard, Dr. Reto Luginbuehl, Prof. Yannis Missirlis, Dr. Matthias Buhmann, Dr. Vesna Miskovic-Stankovic, Dr. Veronique Fontaine, Dr. Jose-Ramon Sarasua. Project PTDC/BTM-SAL/29335/2017, Portuguese Government, Fundação para a Ciência e Tecnologia (FCT), and designer Nuno Monge is acknowledged for assistance with the artworks of Figures, and. Publisher Copyright: © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

PY - 2019/5

Y1 - 2019/5

N2 - In Europe, the mean incidence of urinary tract infections in intensive care units is 1.1 per 1000 patient-days. Of these cases, catheter-associated urinary tract infections (CAUTI) account for 98%. In total, CAUTI in hospitals is estimated to give additional health-care costs of £1–2.5 billion in the United Kingdom alone. This is in sharp contrast to the low cost of urinary catheters and emphasizes the need for innovative products that reduce the incidence rate of CAUTI. Ureteral stents and other urinary-tract devices suffer similar problems. Antimicrobial strategies are being developed, however, the evaluation of their efficacy is very challenging. This review aims to provide considerations and recommendations covering all relevant aspects of antimicrobial material testing, including surface characterization, biocompatibility, cytotoxicity, in vitro and in vivo tests, microbial strain selection, and hydrodynamic conditions, all in the perspective of complying to the complex pathology of device-associated urinary tract infection. The recommendations should be on the basis of standard assays to be developed which would enable comparisons of results obtained in different research labs both in industry and in academia, as well as provide industry and academia with tools to assess the antimicrobial properties for urinary tract devices in a reliable way.

AB - In Europe, the mean incidence of urinary tract infections in intensive care units is 1.1 per 1000 patient-days. Of these cases, catheter-associated urinary tract infections (CAUTI) account for 98%. In total, CAUTI in hospitals is estimated to give additional health-care costs of £1–2.5 billion in the United Kingdom alone. This is in sharp contrast to the low cost of urinary catheters and emphasizes the need for innovative products that reduce the incidence rate of CAUTI. Ureteral stents and other urinary-tract devices suffer similar problems. Antimicrobial strategies are being developed, however, the evaluation of their efficacy is very challenging. This review aims to provide considerations and recommendations covering all relevant aspects of antimicrobial material testing, including surface characterization, biocompatibility, cytotoxicity, in vitro and in vivo tests, microbial strain selection, and hydrodynamic conditions, all in the perspective of complying to the complex pathology of device-associated urinary tract infection. The recommendations should be on the basis of standard assays to be developed which would enable comparisons of results obtained in different research labs both in industry and in academia, as well as provide industry and academia with tools to assess the antimicrobial properties for urinary tract devices in a reliable way.

KW - antimicrobial

KW - device-associated urinary tract infections

KW - in vitro

KW - in vivo

KW - material testing

UR - http://www.scopus.com/inward/record.url?scp=85065484534&partnerID=8YFLogxK

U2 - 10.1002/mabi.201800384

DO - 10.1002/mabi.201800384

M3 - Review article

C2 - 30884146

AN - SCOPUS:85065484534

SN - 1616-5187

VL - 19

JO - Macromolecular Bioscience

JF - Macromolecular Bioscience

IS - 5

M1 - 1800384

ER -

Evaluating Efficacy of Antimicrobial and Antifouling Materials for Urinary Tract Medical Devices: Challenges and Recommendations

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this